Anti-fungal Therapy Using a Combined Drugs Protocol

Brief Description

Many immunocompromised patients suffer from pulmonary and central nervous system fungal infections caused by pathogens such as C. neoformans. The current standard treatment entails intravenously administrating anti-fungal agents that are extremely toxic. In addition, new structural and mechanistic classes of antifungal therapeutics are needed to improve treatment options and to counter increasing resistance to currently used agents. This invention identifies and validates a novel treatment regime entailing a combination of two drugs.


Dr. Damian Krysan of the URMC has found that a combined therapy of a known antifungal agent and an FDA approved metastatic breast cancer drug are a much better and more powerful treatment regimen against fungal infections. Furthermore, this regimen has the potential to be used prophylactically in patients at risk of infection.


Current therapy has major risks including toxic side effects and is given intravenously. This combination of drugs is at low doses and can be given orally. Most addition, both drugs involved in this combination therapy are FDA approved so the path to clinical approval is significantly reduced.

Patent Information:
Title Country Patent No. Issued Date
Compounds for Anti-Fungal Treatment United States 9,040,570 5/26/2015
For Information, Contact:
Scott Catlin
Associate Vice President
University of Rochester
Damian Krysan
Infectious Disease